Valuation: Armata Pharmaceuticals, Inc.

Market Cap 121M 108M 99.86M 90.36M 169M 11.51B 172M 1.19B 475M 6.02B 454M 444M 19.07B P/E 2026 *
-1.74x
P/E 2027 * -2.25x
Enterprise Value 121M 108M 99.86M 90.36M 169M 11.51B 172M 1.19B 475M 6.02B 454M 444M 19.07B EV / Sales 2026 *
28.4x
EV / Sales 2027 * 43.9x
Free-Float
32.36%
Yield 2026 *
-
Yield 2027 * -
1 day-1.22%
1 week-5.80%
Current month-11.44%
1 month-9.47%
3 months-28.88%
6 months-65.97%
Current year-48.25%
1 week 3.15
Extreme 3.15
3.84
1 month 2.74
Extreme 2.745
4.07
Current year 2.74
Extreme 2.745
14.98
1 year 2.74
Extreme 2.745
14.98
3 years 0.9
Extreme 0.8981
16.34
5 years 0.83
Extreme 0.8311
16.34
10 years 0.83
Extreme 0.8311
16.34
Manager TitleAgeSince
Chief Executive Officer 70 11/07/2023
Director of Finance/CFO 42 16/08/2024
Chief Operating Officer - -
Director TitleAgeSince
Director/Board Member 62 09/05/2019
Director/Board Member 66 12/02/2020
Director/Board Member 51 12/02/2020
Date Insider Type Main position Quantity % Market Cap. Importance
10/7/26 Tax

Chief Executive Officer

-14,041 0.0382%
24/4/26 Free

Director

51,280 0.1400%
14/3/26 Tax

Public Communications Manager

1,030 0.0028%
Change 5-day change 1-year change 3-year change Capi.($)
-1.22%-5.80%-40.48%+57.77% 122M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
-0.67%-2.10%+22.58%-11.21% 24.23B
Average -0.21%+4.61%+43.09%+152.15% 39.27B
Weighted average by Cap. +0.06%+3.59%+49.23%+160.51%

Financials

2026 *2027 *
Net sales 4.25M 3.81M 3.51M 3.18M 5.94M 405M 6.04M 41.9M 16.72M 212M 15.95M 15.61M 671M 2.75M 2.46M 2.27M 2.06M 3.85M 262M 3.91M 27.11M 10.82M 137M 10.32M 10.1M 434M
Net income -76.6M -68.61M -63.3M -57.28M -107M -7.29B -109M -755M -301M -3.82B -287M -281M -12.09B -72M -64.49M -59.5M -53.84M -101M -6.86B -102M -710M -283M -3.59B -270M -264M -11.37B
Net Debt - -
Projected Income Statement - Annual - Armata Pharmaceuticals, Inc.
Logo Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. It is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection. Its AP-PA03 is focused on the treatment of acute ventilator-associated pneumonia.
Employees
61
Date Price Change Volume
29/10/26 US$3.250 -1.22% 102,851
28/10/26 US$3.290 -5.73% 62,135
27/10/26 US$3.490 +1.16% 104,310
26/10/26 US$3.450 -5.22% 63,646
23/10/26 US$3.640 +5.51% 115,590
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Armata Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.250USD
Average target price
17.50USD
Spread / Average Target
+438.46%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Armata Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. ARMP Stock